RPG Life Sciences Limited reported an 8.3% increase in revenue to ₹707.5 crore for FY26, driven by sustained growth momentum across its business segments. The company achieved robust profitability with an EBITDA margin of 24.4%, translating to an EBITDA of ₹172.7 crore. This financial performance was disclosed during the RPG Annual Investor Conference 2026 held on May 26, 2026.

The company demonstrated strong return ratios, recording a Return on Capital Employed (ROCE) of 28.5% and a Return on Equity (ROE) of 21.1%. Earnings per share (EPS) stood at ₹69.6, supported by operational efficiency. RPG Life Sciences has invested over ₹185 crore in capital expenditure over the last five years to fuel growth and capacity expansion.

Financial Performance

The domestic formulations business, contributing 69% to sales, outperformed the Indian Pharma Market (IPM) with a growth rate 1.6 times that of the market. The company reported a 13.7% growth in domestic formulations for the full year FY26, compared to an IPM growth of 8.6%. Key brands like Naprosyn grew by 16% during the year.

Strategic Initiatives

Management attributed the market-beating growth to a focus on high-growth therapy areas such as nephrology, rheumatology, and oncology. The company also emphasized volume-led growth, recording a 6.4% volume increase compared to the IPM volume growth of 0.7%. New product launches contributed 4.1% to the overall growth.

RPG Life Sciences continues to focus on cost optimization, capacity utilization, and strengthening its digital ecosystem to drive future value creation.

RPG Life Sciences Limited has reported its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at its meeting held on April 29, 2026, which commenced at 03:00 PM (IST) and concluded at 6:30 PM (IST). The statutory audit was conducted by S R B C & CO LLP, Chartered Accountants, who issued an unmodified opinion on both the standalone and consolidated financial statements. Subsequently, the transcript of the Results Earnings Call held on April 30, 2026, at 3:30 PM (IST) has been made available on the company's website.

Standalone Financial Performance

On a standalone basis, RPG Life Sciences delivered revenue from operations of Rs. 70,752 lakhs for the year ended March 31, 2026, compared to Rs. 65,343 lakhs in the previous year. Total income for the full year stood at Rs. 73,306 lakhs versus Rs. 66,611 lakhs in FY25. Total expenses for FY26 were Rs. 58,276 lakhs against Rs. 51,583 lakhs in FY25. The company's profit before exceptional items and tax remained broadly stable at Rs. 15,030 lakhs in FY26 compared to Rs. 15,028 lakhs in FY25. After accounting for exceptional items of Rs. 390 lakhs (net) in FY26 versus Rs. 8,260 lakhs in FY25, profit before tax stood at Rs. 15,420 lakhs compared to Rs. 23,288 lakhs in the prior year. Net profit for FY26 was Rs. 11,517 lakhs, against Rs. 18,324 lakhs in FY25.

The following table summarises the key standalone financial metrics:

Consolidated Financial Performance

On a consolidated basis, which includes subsidiary RPG Active Pharma Limited, the company reported revenue from operations of Rs. 70,752 lakhs and total income of Rs. 73,310 lakhs for FY26. Total consolidated expenses stood at Rs. 58,280 lakhs. Profit before exceptional items and tax was Rs. 15,030 lakhs, while profit before tax was Rs. 15,420 lakhs. Net profit for the consolidated entity was Rs. 11,517 lakhs for FY26, compared to Rs. 18,324 lakhs in FY25. Total comprehensive income for the period was Rs. 11,453 lakhs versus Rs. 18,214 lakhs in the prior year. Basic and diluted earnings per share (of Rs. 8/- each, not annualised for the quarter) stood at Rs. 69.64 for FY26 compared to Rs. 110.80 in FY25.

Exceptional Items

The exceptional items for FY26 reflect several non-recurring developments. The following table details the components:

Regarding the fire incident at the company's API plant in Navi Mumbai, the insurance company acknowledged a claim amount of Rs. 3,137 lakhs as full and final settlement. The Group had recognised a cumulative loss of Rs. 2,295 lakhs up to December 31, 2025, and received Rs. 2,050 lakhs in multiple tranches up to that date. The balance of Rs. 1,087 lakhs was received in two tranches — Rs. 652 lakhs during Q4 FY26 and Rs. 435 lakhs in April 2026. Additionally, the Group received a final settlement of Rs. 791 lakhs towards compensation for loss of profit due to business interruption, recognised under Other Income for Q4 FY26. The impact of the New Labour Codes, notified by the Government of India on November 21, 2025, resulted in an incremental provision of Rs. 1,169 lakhs for FY26, primarily due to a change in wage definition. An impairment of intangible assets under development amounting to Rs. 916 lakhs was also charged off during Q4 FY26.

Dividend and Corporate Actions

The Board of Directors has recommended a final dividend of Rs. 24 (Rupees Twenty Four only) per equity share, representing 300% on the face value of Rs. 8 per share, for FY 2025-26. This is subject to approval of shareholders at the ensuing Annual General Meeting and will be paid or dispatched within 30 days of such approval. The Board also approved the appointment of Dr. Pratit Samdani (DIN: 10139232) as an Additional Non-Executive Independent Director for a period of five years from April 29, 2026 to April 28, 2031, not liable to retire by rotation, subject to shareholder approval. Dr. Samdani is one of Mumbai's recognised physicians with over two decades of experience in Internal Medicine and Critical Care, and has contributed to research in Diabetes, Hypertension, Infectious Diseases, and Intensive Care Medicine. He holds a Gold Medal in F.C.P.S. (Medicine) and secured Second Rank in M.D. (Internal Medicine) from Bombay University, and has published in journals including the British Medical Journal (BMJ) and JAMA India. Dr. Samdani is not related to any Director or Key Managerial Personnel of the Company.

Balance Sheet and API Division Transfer

As at March 31, 2026, consolidated total assets stood at Rs. 79,316 lakhs compared to Rs. 65,781 lakhs as at March 31, 2025. Total equity was Rs. 60,535 lakhs versus Rs. 53,053 lakhs in the prior year. Cash and cash equivalents on a consolidated basis were Rs. 15,046 lakhs at year-end, up from Rs. 2,870 lakhs at the start of the year. The Board of Directors had approved, at its meeting held on December 15, 2025, the transfer of the API division of the Company to its wholly owned subsidiary, RPG Active Pharma Limited, which was incorporated on December 24, 2025, subject to receipt of all requisite consents and approvals. The company also amended its Code of fair disclosure, internal procedures and conduct for regulating, monitoring and reporting of trading by designated persons.

Earnings Call Transcript

In continuation of its earlier communications dated April 23, 2026 and April 30, 2026, RPG Life Sciences has informed the stock exchanges that the transcript of the Results Earnings Call held on April 30, 2026, at 3:30 PM (IST) — covering the audited financial results for the quarter and year ended March 31, 2026 — has been made available on the company's website. The disclosure was filed with the exchanges on May 08, 2026.